Seroepidemiological study of Epstein-Barr virus infection in Bangladesh.
A seroepidemiological study was carried out on 502 sera to determine the prevalence of EBV infection in a group of Bangladeshi people (age range: 15 days-90 years). All sera were tested for IgG antibody to the EBV viral capsid antigen (VCA) by a commercially available enzyme linked immunosorbent assay (ELISA) and the negative sera were checked subsequently by indirect immunofluorescence (IF) methods. The prevalence of EBV infection in the study group was 81.27%. 42.37% of infants had antibodies to EBV by the age of 1 year. A significant rise in the percentage of seropositives between 0-1- and 1-2-year-old children was demonstrated, indicating a high rate of primary infection at these ages. The prevalence of IgG antibody to VCA was 87.93% in the 2-10 years age group and was sustained at over 85% thereafter. Higher ELISA values were more common both in the 0-2- and > 25-year age groups, the latter being statistically significant (P < 0.025). Similar higher values were also observed in females as compared to males (P = 0.05). Eighteen out of 109 negative sera and two equivocal sera by ELISA were found to be positive by indirect IF, indicating a negative predictive value of 82% for ELISA. The concordance between the two methods was 97% with ELISA proving to be less sensitive than indirect IF. It is concluded that the prevalence of EBV infection in Bangladeshi population is similar to that observed in other developing countries and that ELISA can be used for seroepidemiological surveys; however, the sera negative by ELISA should be checked routinely by indirect IF.
Haque
T
T
Department of Clinical Sciences, London School of Hygiene and Tropical Medicine, United Kingdom.
Iliadou
P
P
Hossain
A
A
Crawford
D H
DH
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000914:Antibodies, Viral / Q000097:blood*; D001459:Bangladesh; D002213:Capsid / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D003967:Diarrhea / Q000097:blood / Q000453:epidemiology / Q000276:immunology / Q000821:virology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D019084:Fluorescent Antibody Technique, Indirect; D006566:Herpesviridae Infections / Q000097:blood / Q000453:epidemiology / Q000276:immunology / Q000821:virology*; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011933:Reagent Kits, Diagnostic; D014412:Tumor Virus Infections / Q000097:blood / Q000453:epidemiology / Q000276:immunology / Q000821:virology*
D000914:Antibodies, Viral; D007074:Immunoglobulin G; D011933:Reagent Kits, Diagnostic